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ABSTRACT
TEP1 is a protein component of two ribonucleo-
protein complexes: vaults and telomerase. The vault-
associated small RNA, termed vault RNA (VR), is
dependent upon TEP1 for its stable association
with vaults, while the association of telomerase
RNA with the telomerase complex is independent of
TEP1. Both of these small RNAs have been shown to
interact with amino acids 1–871 of TEP1 in an indirect
yeast three-hybrid assay. To understand the determi-
nants of TEP1–RNA binding, we generated a series of
TEP1 deletions and show by yeast three-hybrid assay
that the entire Tetrahymena p80 homology region
of TEP1 is required for its interaction with both
telomerase and VRs. This region is also sufficient to
target the protein to the vault particle. Electrophoretic
mobility shift assays using the recombinant TEP1
RNA-binding domain (TEP1–RBD) demonstrate that
it binds RNA directly, and that telomerase and VRs
compete for binding. VR binds weakly to TEP1–RBD
in vitro, but mutation of VR sequences predicted to
disrupt helices near its central loop enhances
binding. Antisense oligonucleotide-directed RNase
H digestion of endogenous VR indicates that this
region is largely single stranded, suggesting that
TEP1 may require access to the VR central loop for
efficient binding.
INTRODUCTION
Vaults are 13 million Dalton ribonucleoprotein particles
(RNPs) of unknown function with dimensions of 42 · 75 nm
(1–3). Vault morphology is reminiscent of a barrel with a cap
on each end and is highly conserved across a wide range of
species. The basic vault structure is formed by multimerization
of a predicted 96 copies of the 96 kDa major vault protein
(MVP), which makes up >70% of the particle mass and forms
the entire exterior shell of vaults (4). Virtually all of the MVPs
of the cell biochemically fractionate as a large particle, sug-
gesting that all or most MVP monomers are incorporated into
vaults. Although the function of vaults has not been determ-
ined, roles have been proposed with respect to nucleocytoplas-
mic trafficking, multi-drug resistance and, more recently, as a
scaffold for epidermal growth factor signaling (5–9). Despite
their presence in a wide variety of evolutionarily diverse
organisms and upregulation in several multi-drug resistant
cancer cell lines, mammalian vaults are not required for
survival, as mice lacking MVP are viable, do not display
increased sensitivity to cytostatic drugs, and have no obvious
phenotypic defects (10).
Vaults contain two other proteins: vault poly (ADP-ribose)
polymerase (VPARP) and telomerase-associated protein 1
(TEP1), as well as a small untranslated vault RNA (VR)
(11–13). Each of these components is present in multiple
copies in vaults, but their precise stoichiometry with respect
to a single vault is unclear, and it is not known whether all
vaults contain equal numbers of these components. Moreover,
some species, such as human and bullfrog, express multiple-
related VRs that can associate with the vault particle (8,11).
Cryoelectron microscope (cryoEM) image reconstructions of
intact or RNase-treated vaults purified from rat liver have
resolved the structure to 31 and 22 s resolutions, respectively.
Difference imaging between intact and RNase-treated vaults
localizes VR to the interior ends of each of the vault caps
(3,14). The precise localization of VPARP and TEP1 within
the vault particle is not yet known. Both proteins, as well as
VR, are also found in non-vault-associated fractions within the
cell (8,12,13).
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TEP1 is an RNA-binding protein that interacts with
mammalian telomerase in cell extracts and was cloned
based upon its homology with Tetrahymena p80, which
also co-purified with telomerase activity and binds the
Tetrahymena telomerase RNA (TR) in vitro (15–17). A
schematic illustration of the various domains identified in
TEP1 is shown in Figure 1. Disruption of the p80/p95 complex
in Tetrahymena leads to telomere lengthening (18). However,
p80 is not a core telomerase component and is not required for
telomerase activity (18–20). Furthermore, recombinant p80
binds poorly or not at all to other co-expressed telomerase
subunits in Escherichia coli or insect cell extracts and non-
specifically interacts with a number of RNAs in vitro, in addi-
tion to its interaction with TR (19). The precise function of
mammalian TEP1 is also not known, but it has been shown to
be one of four components of purified vaults and to interact
with the VR and mammalian TR in an indirect yeast
three-hybrid assay (13,16). Immunoprecipitation of endogen-
ous TEP1 co-immunoprecipitates telomerase activity
(16,17). Despite the in vitro association between TEP1 and
telomerase activity, Tep1-deficient mice have no known
telomerase-related defect, as telomerase activity, TR levels
and telomere length are normal in these mice (21,22). How-
ever, VR levels are reduced in all tissues studied from Tep1-
deficient mice and VR stability is markedly reduced in mouse
embryonic fibroblasts (MEFs) derived from these mice in
comparison with MEFs derived from wild-type mice. Further-
more, vaults purified from Tep1-deficient mice do not contain
VR, demonstrating genetically and biochemically that TEP1 is
required for the association of VR with the vault particle (22).
VPARP is a member of the PARP family of proteins and is
the only vault-associated protein demonstrated to have enzym-
atic activity, as it is able to ADP-ribosylate both itself and
MVP in vitro, although the functional significance of this
modification is not known (12). In addition to its localization
in the vault particle, VPARP is seen at the mitotic spindle
using immunofluorescence, and immunoprecipitation of
VPARP from lysates derived from VPARP transfected cells
results in the co-immunoprecipitation of telomerase activity
(12,23). Like TEP1, Vparp-deficient mice also have no known
phenotypic defects, telomerase-related or otherwise (22,23).
Vaults purified from livers of either Vparp- or Tep1-deficient
mice also appear morphologically normal (22,23).
VR is an RNA polymerase III transcript that does not appear
to be further processed, and thus retains its 30 polyuridylate
tail, binds the La autoantigen in vitro and is found stably
complexed with La apart from the vault particle in vivo
(24). Interestingly, La has also been found to co-purify with
vaults purified from rat livers. The genes for VR have been
identified and sequenced for a variety of species, and the
RNAs are all predicted to fold into a highly conserved
structure (8,25). Some species, such as humans and bullfrogs,
express multiple-related VRs, and two species, humans and
mouse, each contains a VR pseudogene (8,25,26). The func-
tion of VR is not known, but as it is unimportant for the
structural integrity of the vault particle, it is proposed to
play a functional rather than structural role in the com-
plex (14,27).
The goal of the current study is to determine whether TEP1,
a component of both vault and telomerase RNPs, each
containing an unrelated RNA, VR or TR, binds singly or
simultaneously to these RNA species. Using the yeast
three-hybrid system, we determined that the entire TEP1
Tetrahymena p80 homology region is required for its interac-
tion with VR and TR. Electrophoretic mobility shift assays
(EMSAs) using a partially purified truncation of TEP1 con-
taining this RNA-binding domain (TEP1–RBD) demonstrate
that TEP1 can indeed bind RNA directly, and that, like p80,
TEP1 also binds some RNAs non-specifically. However,
although TR binds to TEP1–RBD in vitro, only point mutants
of mVR that are predicted to disrupt base-pairing near the VR
central loop were able to interact with TEP1–RBD, suggesting
that other factors are normally required for this association.
Furthermore, competition experiments indicate that there is
likely only one RNA-binding site, since VR and TR do not
simultaneously bind to TEP1–RBD. RNase H digests of
extracts containing VR annealed to complementary DNA oli-
gonucleotides (ODNs) were synthesized in order to identify
single-stranded regions of VR. These experiments suggest that
the central loop of partially purified endogenous VR forms a
more open and single-stranded structure than predicted by
thermodynamic models. Combined with the results of our
Figure 1. Yeast three-hybrid analysis of TEP1 deletions and vault/telomerase
RNAs. (A) TEP1 truncations were made using amino acids 1–871 as a starting
point, since this region of human TEP1 interacts with human vault and telo-
merase RNAs in the yeast three-hybrid system (16). (B) Yeast strain L40i was
transformed with plasmids expressing the above TEP1 deletions and murine
vault or telomerase RNA in either sense (s) or antisense (as) orientations. Yeast
were grown on synthetic drop-out plates lacking uracil, leucine and histidine,
and containing 5 mM 3-aminotriazole (+3AT) or synthetic media lacking only
uracil and leucine (3AT). Growth on +3AT media indicates a TEP1–RNA
interaction. No TEP1 deletions interacted with antisense RNA constructs (data
not shown), but this is shown above only for those TEP1 deletions that interact
with RNA in the sense orientation (constructs 1 and 2).
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VR mutations, these results suggest that the central loop of VR
is important for its interaction with TEP1. Finally, by purifying
recombinant vaults generated by co-infecting Sf9 insect cells
with baculoviruses expressing MVP and a series of TEP1
truncations, we show that the p80 homology region of
TEP1 also contains the vault-interaction domain.
MATERIALS AND METHODS
Yeast three-hybrid analysis
Mouse TEP1 deletions were generated by PCR, cloned into the
pACT II yeast expression vector and confirmed by sequence
analysis. PCR primers were engineered to contain an NcoI site
for cloning purposes and are as follows. Forward primers for the
followingTEP1amino acid sequences1–871,1–740and1–580:
50-AATCCATGGCTATGGAGAAGCTCTGTGGGCATG-30;
201–871: 50-AATCCATGGCTCAAGAAGAAGAAAGCAC-
AGAAG-30; 270–871: 50-AATCCATGGCTTCTGACCTTA-
CCCGGGCATC-30; and 400–871: 50AATCCATGGCTCG-
CCCTCAAAAGACAGAACG-30. Reverse primers: 1–871,
201–871, 270–871 and 400–871: 50-AATCCATGGTATGG
TATCTAGTTGTCCC-30; 1–740: 50-AAT CCATGCGGTGT-
CTTCACAAATCCTCC-30; and 1–580: 50-AATCCATGATC-
GATAGAGTCATGAGC-30. Mouse VR was cloned by PCR
into the SmaI site of pIII/MS2-1 in sense and antisense
orientations using the following primers: forward, 50-CTGA-
CCCGGGCCAGCTTTAGCTCAGC-30; reverse, 50-TTGAC-
CCGGGAAAGGGCCAGGGAGCGCC-30. Murine TR clones
for use in the yeast three-hybrid system have been published
previously (16). Plasmids were transformed into the L40i yeast
strain and tested for TEP1–VR and TEP1–TR interactions as
described previously (13,16,28).
TEP1–RBD expression and partial purification
The DNA sequence for amino acids 201–871 of murine
TEP1 was PCR amplified and cloned into pET28a using for-
ward and reverse primers containing engineered SalI and NotI
sites, respectively, thus fusing the His-T7 tag onto the
N-terminus of TEP1–RBD. Forward primer, 50-ATCTGT-
CGACAAGAAGAAGAAAGCACAGA AG-30; reverse
primer, 50-ATAAGAATGCGGCCGCTTATAGTTTATCTA-
GTTGTCCC-30. The plasmid was sequenced and trans-
formed into BL21 CodonPlus DE3 E.coli (Stratagene). A
500 ml culture was induced with 1 mM Isopropyl-b-D-
thiogalactopyranoside for 2.5 h at 21C, and lysed in 50 mM
NaH2PO4, pH 8, 300 mM NaCl, 0.5% v/v Triton X-100,
10 mg/ml leupeptin by a 1 h incubation with 1 mg/ml lysozyme
at 4C followed by sonication (two 10 s pulses at setting 3.5).
Cleared lysates were applied to a Ni-NTA column (Novagen)
and washed according to the manufacturer’s protocol with the
final wash and elution containing 100 and 250 mM imidazole,
respectively. The eluate was dialyzed into 20 mM Tris, pH 8,
150 mM NaCl, 1 mM MgCl2, 10% glycerol and 1 mM DTT,
and stored at 80C.
Mutagenesis, EMSA and immunoprecipitation
VR and TR were PCR amplified using a forward primer
engineered to incorporate a T7 promoter sequence to drive
transcription and cloned into pUC 118. Point mutants were
generated using the Quickchange Mutagenesis Kit (Strata-
gene), or by a second round of PCR using a transcription
template (see below) using a forward or reverse primer incorp-
orating the appropriate nucleotide alteration. Transcription
reactions were performed using sequenced VR or TR PCR
product templates derived from pUC 118 clones to ensure
correct termination of transcription. EMSA was performed
as described previously (24) with the following exception:
5 fmol of 32P-CTP radiolabeled RNA was used in each binding
reaction and native gels were electrophoresed at 300 V in 0.5·
TBE for 1 and 4 h for VR and TR probes, respectively. Com-
petitions were carried out by pre-incubating unlabeled RNA
with TEP1–RBD for 10 min prior to the addition of
radiolabeled RNA. Dried gels were exposed to PhosphorIm-
ager screens and imaged using the Typhoon 9410 (Molecular
Dynamics). Immunoprecipitation of mTR/TEP1–RBD com-
plexes was carried out by transferring the binding reaction into
90 ml 1· binding buffer containing 0.1 mg/ml BSA, followed
by incubation with 1 mg antibody on ice for 40 min. Fifteen ml
Protein A beads were then used to capture the complex by
tumbling the tubes for 20 min at 4C. The beads were washed
three times with ice-cold binding buffer and boiled in SDS
sample buffer.
RNase H digests
RNase H assays were performed on either P100 extract (RNP)
or deproteinized P100 extract (RNA) prepared from either rat
fibroblasts or HeLa cells. Antisense ODNs that span almost the
entire length of rat VR or human VR1 were synthesized on an
Applied Biosystems DNA synthesizer. Ten micrograms of
total protein (P100) or deproteinized P100 (RNA), 0.5 mg
of antisense ODNs and 0.4 U of RNase H (in a final volume
of 25 ml) were incubated at 30C for 1 h. Reactions were
phenol:chloroform extracted, and ethanol precipitated in the
presence of 10 mg of carrier tRNA and analyzed by northern
blotting as described previously (8).
Baculoviruses, SF9 insect cell infections and
vault purifications
The rat MVP-encoding baculovirus and human TEP1-
encoding baculovirus have been described previously (4,29).
DNA encoding human TEP1 amino acids 1–1650 and 1–125
were generated by PCR, cloned into pFastBac 1 and verified
by sequencing. The primers used were as follows. The 1–1650
and 1–125 constructs were both made using the forward
primer: 50-CTACGTCGACCACCATGGAAAAACTCCAT-
GGGCATG-30. The reverse primer sequence for the 1–1650
clone encodes a C-terminal T7 epitope tag and is 50-GCTT-
TCTAGACTAACCCATTTGCTGTCCACCAGTCATGCTA-
GCCATGAGGTGCCATCTCCGGGAGAG. The reverse pri-
mer sequence for the 1–125 clone also encodes a C-terminal T7
epitope tag and is 50-GCTTTCTAGACTAACCCATTTGC-
TGTCCACCAGTCATGCTAGCCATGCTGGCAGACAC-
AGTGCTCTTTAG-30. SalI and XbaI sites engineered into the
primers were used to clone the PCR product into pFastBac
(Invitrogen). A fragment of the hTEP1 cDNA, spanning the
first 911 amino acids, was subcloned into pFastBac1 and
engineered with an N-terminal tandem c-myc epitope tag (resi-
dues 408–439 of the human c-myc protein) and a C-terminal 6
histidine tag. The final insert sequence was confirmed using
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fluorescent dideoxy-nucleotide sequencing and automated
detection (ABI/PerkinElmer). The resulting 956 amino acid
fusion protein has a predicted weight of 108.4 kDa. Viruses
were generated according to the protocol of the Bac-to-Bac
system (Invitrogen). Sf9 cells were maintained and infected
with baculovirus(es) as described previously (4). Recombinant
vaults were purified from infected Sf9 cell lysates and
analyzed by western blot as described previously (4).
RESULTS
The entire Tetrahymena p80 homology region of
murine TEP1 is required for the interaction with
vault and telomerase RNAs
A truncation consisting of the first 871 amino acids of murine
TEP1 has been previously shown to interact with mouse TR
and multiple human VRs using a yeast three-hybrid assay
(13,16). Briefly, this assay fuses an RNA of interest to the
MS2 phage hairpin RNA, which binds to the MS2 coat protein,
and can be used to test RNA–protein interactions by driving
transcription of a reporter gene in a manner analogous to yeast
two-hybrid assays (28). In addition to the p80 region, this 871
amino acid sequence contains four N-terminal 30 amino acid
repeats of unknown significance. Since the region of homo-
logy between TEP1 and p80 is poorly conserved with other
RNA-binding proteins at key residues (30), we decided to test
a series of TEP1 truncations for two reasons: first, to determine
whether it was possible to separate the RNA-binding activities
for VR and TR, which might suggest a functional connection
between the two RNAs; and second, if this was not possible, to
further define the region of TEP1 critical for binding RNA.
TEP1 deletions were made using the 1–871 amino acid region
as a starting point (Figure 1A), and these constructs were
transformed into the L40i yeast strain, along with plasmids
expressing mTR and mVR sense and control, antisense RNAs
fused to the MS2 hairpin RNA. An interaction between protein
and RNA activates the His3 reporter gene and allows the
growth of yeast on media lacking histidine and containing
3-aminotriazole. Both the 1–871 amino acid construct and a
construct lacking the 4 N-terminal repeats of TEP1 (amino
acids 201–871) were able to bind to both TR and VR in sense
but not antisense orientations based on this assay (Figure 1A,
constructs 1 and 2; Figure 1B, 1s, 1as, 2s and 2as). Deletion of
any sequences in the TEP1-p80 homology region resulted
in the loss of RNA-binding ability of both TR and VR
(Figure 1A, constructs 3–6 and Figure 1B, 3–6). Western
blots of transformed yeast cultures verified that all of the
TEP1 deletions were expressed (data not shown), although a
substantial portion of construct 3 (amino acids 270–871) is
found as a smaller breakdown product in yeast lysates. Thus,
the entire p80 homology region (amino acids 201–871) is
required for TEP1 to bind both VR and TR in an indirect
yeast three-hybrid system; henceforth this domain will be
referred to as TEP1–RBD.
Partially purified TEP1–RBD binds TR in vitro
Evidence exists that VR and TR bind to TEP1 in vitro and
in vivo, but it has not yet been shown that TEP1 binds to these
RNAs directly (13,16,22). Therefore, we expressed and
purified from E.coli the murine TEP1–RBD fused to the
HisT7 N-terminal epitope tag derived from pET28 (see
Materials and Methods). We were unable to completely purify
the recombinant protein away from contaminating bacterial
proteins without washing TEP1–RBD off the Ni-NTA resin.
Nevertheless, we were able to partially purify enough recom-
binant TEP1–RBD (Figure 2A) to determine whether it could
interact with RNA in vitro using EMSA. Although full-length
mTR binds to TEP1–RBD using EMSA (data not shown), we
also transcribed mTR nt 1–223, which is sufficient to interact
with TEP1 in the yeast three-hybrid assay (A. Reda and
L. Harrington, unpublished data), rather than full-length
mTR, to facilitate resolution of the RNA and RNP complexes
on native gels. Incubation with increasing amounts of TEP1–
RBD induced a small shift in the mobility of the 223 nt mTR
probe using EMSA (Figure 2B, lanes 1–4), and this association
was competed with pre-incubation of 50· unlabeled full-
length TR (Figure 2B, lane 5). Surprisingly, even 250· excess
unlabeled mVR was unable to compete with the TR probe for
binding to TEP1–RBD (Figure 2B, lane 6), but an mVR vari-
ant (see below) did compete with TR probe, although less
effectively than TR itself (Figure 2B, compare lanes 7–8
with lane 5). Using more than 80 ng TEP1–RBD in the binding
reactions did not result in increased TR binding, nor did using
more than 50-fold molar excess of unlabeled TR result in
much additional competition with labeled probe (data not
shown), indicating that the majority of the RNA is unable
to bind despite a high molar excess of protein to target
RNA. To test the specificity of RNA binding by TEP1, four
non-specific competitor RNAs were used; three RNAs were
unable to compete for binding to TEP1 even at 500· excess
(Figure 2B, lanes 9–11). The NL15 RNA is an artificial RNA
with both single- and double-stranded regions that interacts
with the La protein in vivo, but does not bind in a 30 uridylate
dependent manner (31). La has previously been shown to
interact with the VR and the TR (24,32,33). As La also
interacts with the vault particle, this seemed to be a relevant
RNA to test for binding to TEP1–RBD (24). However,
in vitro transcription of the multiple-cloning site of linearized
pBluescript SK+ containing the T7 promoter yielded an RNA,
which was able to efficiently compete with TR for binding
at 50-fold molar excess (Figure 2B, lane 12). This indicates
that TEP1–RBD, like its Tetrahymena p80 homolog, has
limited specificity with respect to its affinity for RNA
in vitro (19). The specificity of the RNA–protein complex
was then further analyzed since the TEP1–RBD protein
was only partially purified. We used a monoclonal antibody
directed against the T7 epitope tag of the recombinant
TEP1–RBD protein to co-immunoprecipitate the mTR (nt
1–223) probe (Figure 2C, lanes 1 and 2). Control antibodies
(Figure 2C, lanes 3–6) did not bring down either the TEP1–
RBD protein or the mTR RNA, demonstrating that the band
shift seen using EMSA was specifically due to binding to
TEP1–RBD.
A VR variant has an enhanced ability to bind
TEP1–RBD in vitro
Since unlabeled mVR could not compete with TR for binding
to TEP1–RBD in vitro, we repeated the EMSAs using
radiolabeled VR transcripts. When labeled mVR was
896 Nucleic Acids Research, 2005, Vol. 33, No. 3
incubated with TEP1–RBD, no RNP complex was observed,
as might be expected from the inability of mVR to compete
with labeled mTR for binding to TEP1–RBD (Figure 3A, left
panel). In contrast, when we used the related human hVR1, we
detected a low-level interaction with the murine TEP1–RBD
using EMSA (Figure 3A, right panel). We recently reported
that the mouse genome contains two VR genes, mvg1 and
Figure 2. Partially purified murine TEP1–RBD interacts with TR in vitro but
has limited specificity. (A) Amino acids 201–871 of murine TEP1 were
expressed in E.coli and partially purified using the hexahistidine tag derived
from the pET28a vector. Shown are a Coomassie-stained gel (left panel) and
western blot (right panel) using anti-TEP1 polyclonal antibodies. (B) EMSA of
nt 1–223 of mouse TR incubated with TEP1–RBD. Five fmol 32P-labeled probe
was incubated with 0, 5, 20 and 80 ng TEP1–RBD (lanes 1–4). Probe was
competed off with 50· full-length TR (lane 5) and increasing amounts of mVR
double point mutant (lanes 7 and 8), but not wild-type mVR (lane 6). The 250·
unlabeled 5S Ribosomal RNA, tRNAphe or an artificial RNA (NL15) do not
compete with the probe (lanes 7–9), but 50· excess of an artificial RNA derived
from the pBluescript polylinker region does compete efficiently (lane 10).
Labeled RNA is indicated with a black dot and shifted complexes are indicated
with an asterisk. (C) Immunoprecipitation of TEP1–RBD from binding reac-
tions using anti-T7 monoclonal antibody co-immunoprecipitates the TR tran-
script. Equivalent amounts of the bound (B) and unbound (U) fraction were
analyzed by either western blot using anti-TEP1 polyclonal antibody (upper
panel) or by fractionation on a 10% acrylamide/8 M urea gel (lower panel).
The latter gel was dried and radioactive bands visualized by phosphorimager
analysis. Antibodies to the T7 epitope (lanes 1 and 2), but not antibodies to the
FLAG (lanes 3 and 4) and VSVG (lanes 5 and 6) epitopes, immunoprecipitated
both TEP1–RBD and TR.
Figure 3. Mutagenesis of murine VR enhances its binding to TEP1–RBD.
(A) EMSA of VR–TEP1–RBD complexes. Binding reactions contained 5 fmol
of 32P-labeled murine VR (left panel) or human VR1 (right panel) incubated
with 0 (lanes 1 and 4), 20 (lanes 2 and 5) and 80 (lanes 3 and 6) ng of TEP1–
RBD. (B) EMSA of VR probes (5 fmol) without () or with (+) 80 ng TEP1–
RBD in the binding reaction. Wild-type mouse VR interacts poorly or not at all
with TEP1–RBD (lanes 1 and 2), but a highly related sequence in the mouse
genome that is not expressed binds more strongly (lanes 3 and 4). A VR double
point mutant G70A, C73U (lanes 5 and 6) binds more strongly to TEP1–RBD.
Also shown are the corresponding single mutants in mouse VR (lanes 7–10) and
human VR1 (lanes 11 and 12). Labeled RNAs are indicated with a black dot and
shifted complexes are indicated with an asterisk. (C) The thermodynamically
predicted secondary structure of the wild-type (left structure) and double point
mutant (center structure) mouse VR, focusing on the regions of interest only.
Also shown is the entire predicted structure of mouse VR, along with the
position of the double point mutant and the C78 to A mutation, which has
enhanced binding.
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mvg2; however, only mvg1 is expressed (25). The second, a
pseudogene, was the only murine VR clone identified from
our original genomic screen for VR sequences and was ini-
tially presumed to be the one and only VR gene. This VR
pseudogene (henceforth termed CmVR) contains only 8 nt
changes as compared with mVR, and is predicted to form
into the evolutionarily conserved VR structure. Thus, we
had initially expressed the CmVR ‘coding region’ in vitro
using a T7 promoter and determined that this VR pseudotran-
script is also able to interact with TEP1–RBD in mobility
shifts (Figure 3B, lane 4).
This observation provided a starting point for a mutational
analysis strategy to determine why mVR was unable to bind to
TEP1–RBD in vitro. CmVR sequences were replaced with
mVR sequences in a stepwise manner (Table 1) and assayed
for the loss of binding to TEP1 using EMSA. The first column
of Table 1 indicates the position of the 8 nt differences
between CmVR and mVR, and subsequent columns indicate
intermediate mVR sequences after nucleotides were altered to
revert to the mVR sequence 1 or 2 nt at a time. We were able to
revert theCmVR sequence back to the mVR sequence without
losing binding to TEP1–RBD until reversion was attempted at
either nt 70 or 73. Once the key residues responsible for
CmVR’s interaction with TEP1–RBD were identified, these
residues were altered in mVR, and it was confirmed using
EMSA that this mVR double mutant is able to interact with
TEP1–RBD (Figure 3B, compare lanes 4, 6 and 12). The
double mutant alters the base pairing from Watson–Crick to
wobble, and is predicted to open a loop in this region of the VR
(Figure 3C, left and center structures) using the mfold RNA
structure prediction program (34). Because this structure
borders the conserved central loop of VR (defined as the
region where all three arms of the VR converge in the nine
different VR sequences identified across the various species to
date), we hypothesized that mutations opening up the central
loop might also increase TEP1 binding. Novel mutations in
unmodified mVR, which might weaken the stability of the
helix adjacent to the central loop without grossly altering
the predicted structure of VR, were synthesized. One mutation,
C78!A, showed enhanced binding to TEP1–RBD similar to
the mVR double mutant (data not shown) (results summarized
in Figure 3C, right structure).
The specificity of the interaction between the mVR double
mutant and TEP1–RBD was tested using a number of
unlabeled competitor RNAs. Addition of increasing amounts
of TEP1–RBD to the mobility shift binding reactions resulted
in an increasingly intense band representing the mVR double
mutant–protein complex (Figure 4, lanes 1–4). Pre-incubation
with 50· excess of the unlabeled VR double mutant competed
most of mobility shift, as did 50· excess TR (Figure 4, lanes 5
and 6). However, not all of the labeled RNA could be com-
peted, similar to TR competition results (Figure 2B). This VR/
TR competition for binding to TEP1–RBD indicates that it is
likely that either VR or TR, but not both simultaneously, is
able to bind to TEP1. Increasing the amount of TEP1–RBD to
more than 80 ng did not result in increased VR binding, nor did
incubation with more than 50· unlabeled VR double mutant
result in additional competition with labeled probe (data not
shown). The same four non-specific competitor RNAs were
used as with labeled TR, with identical results; again only the
SK+ transcript was able to compete for binding (Figure 4,
lanes 7–10). Addition of the anti-T7 monoclonal antibody
to the binding reaction also resulted in a faint supershift on
EMSA (data not shown).
RNase H mapping of VR indicates that regions
surrounding the central loop are single stranded
We hypothesized that in vivo the central loop of the VR may be
in a more open conformation that may facilitate TEP1 binding.
To determine whether sequences in the central loop of
the VR were available for base pairing, we used an
oligodeoxynucleotide-directed RNase H cleavage assay
(35). We undertook a preliminary analysis of the secondary
structure of both rat VR (Figure 5, left panels), which is highly
related to murine VR, and human VR1 (Figure 5, right panels)
using this assay. Vault-associated VR was obtained from
Table 1. Stepwise reversion of CmVR to mVR sequence
Nucleotide CmVR 1 2 3 4 5 6 mVR
16 G G G C C C C C
28 U U C C C C C C
36 U U G G G G G G
70 A A A A A A G G
73 U U U U U C U C
91 G G G G A A A A
100 A A A A G G G G
121 G C C C C C C C
Binding + + + + + – – 
The position of the 8 nt differences between the two RNAs are shown in the
leftmost column, and the base found in CmVR and mVR at each is indicated.
Columns 1–6 are variant VRs tested for binding to TEP1–RBD, with the result
shown in the bottom row.
Figure 4. The mVR point mutant competes with TR for binding to TEP1–RBD.
EMSA of mVR double point mutant incubated with 0, 5, 20 and 80 ng of TEP1–
RBD (lanes 1–4). Unlabeled mVR mutant or mouse TR (50·) competes with the
labeled probe (lanes 5 and 6). Three irrelevant RNAs do not compete with TR
for binding to TEP1–RBD (lanes 7–9), but the pBluescript transcript does
compete efficiently (lane 10) as in Figure 2. Labeled RNA is indicated with
a black dot and shifted complexes are indicated with an asterisk.
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resuspended high speed (100 000 g) pellets and deproteinated
VR obtained from phenol:chloroform extraction of these
resuspended pellets. A series of overlapping ODNs comple-
mentary to the VRs were each annealed to VR from either rat
fibroblast or HeLa cell lysates for rat and human VRs, respect-
ively. RNase H was then added to cleave RNA–DNA hybrids,
which form in regions where RNA secondary structure is
largely single stranded (35). The extent of cleavage of the
141 nt rat VR was analyzed by northern blotting (Figure
5A). In the absence of VR-associated vault proteins, three
ODNs, 21–40, 54–70 and 68–85, directed nearly complete
cleavage of rat VR (Figure 5A, lower left panel, RNA).
In addition, antisense ODNs 11–27, 38–53 and 102–125
also led to varying amounts of digestion of the VR, whereas
the remaining four ODNs (80–95, 103–118, 110–129 and
126–143) had either no effect or directed <5% cleavage of
the VR. When vault proteins remain associated with VR, a
similar pattern of cleavage is seen by ODNs 21–40, 54–70 and
68–85 (Figure 5A, upper left panel, RNP), whereas the remain-
ing seven ODNs were presumably unable to hybridize with
VR, as only minimal cleavage of the VR was observed. These
results suggest that bases 21–40 and 54–85 are in an open
conformation available for base pairing in the VR whether
or not protein is associated. These data are inconsistent
with the predicted secondary structure of the rat VR, which
indicates that bases 25–85 are base paired in a stem–loop
structure (Figure 5B, left panel) (11). Similar results were
obtained using ODN-directed cleavage of the 98 nt human
VR (hVR1). In the absence of VR-associated vault proteins,
ODNs 21–38 and 50–65 directed complete cleavage of hVR1,
and ODN 39–53 led to partial cleavage (Figure 5A, lower right
panel, RNA). In the presence of vault proteins, these three
ODNs again led to the most substantial cleavage of VR.
According to these data, both rat and human VR have a sig-
nificantly more open structure in vivo in the regions surround-
ing the central loop than was predicted by thermodynamic
models (Figure 5B, left and right panels). We found minor
differences between protein-bound and deproteinated RNA,
but overall the rat and human VRs were found to be single
stranded in regions of VR that are poorly conserved in
sequence across species. That may indicate that it is the struc-
ture and not the sequence per se that is important for TEP1–
RBD binding.
The p80 region of TEP1 also binds vaults
Although TEP1 did not interact with either MVP or VPARP in
a yeast two-hybrid assay (36), TEP1 does interact directly with
MVP, as co-infection of baculoviruses expressing TEP1 and
MVP generates vault-like particles in insect cells that, when
purified, contain TEP1 (29). Thus, TEP1 may be able to inter-
act with intact vault particles but not MVP monomers. In order
to identify a TEP1–MVP interaction domain, we generated a
series of TEP1 truncations for use in the baculovirus expres-
sion system (Figure 6A). Baculoviruses expressing the various
TEP1 truncations were then used to infect Sf9 insect cell
cultures, either alone or in combination with an MVP-
expressing baculovirus. Vaults were purified from the
co-infected cells as described previously (4). As a final puri-
fication step, fractions enriched in recombinant vaults are
layered over a 10–60% discontinuous sucrose gradient; vaults
comprising HisT7-epitope tagged MVP subunits were used in
this study. These particles fractionate predominantly in the
45% sucrose layer (Figure 6B, ‘MVP’ panel). When TEP1
truncations were expressed without MVP, the vault purifica-
tion scheme removed each truncation prior to the sucrose
gradient step [Figure 6B, 1–3, upper () panels]. When
expressed together with MVP [Figure 6B, 1–3, lower (+) pan-
els], some TEP1 truncations were seen to co-purify with the
recombinant vaults [Figure 6B, 1–3, lower (+) panels]. Trun-
cations consisting of amino acids 1–1650 and 1–911
(Figure 6A, constructs 1 and 2; Figure 6B, panels 1 and 2)
each co-purified with vaults, whereas a truncation consisting
of amino acids 1–125, which contains the 4 N-terminal
repeats, failed to interact (Figure 6A, construct 3 and
Figure 6B, panel 3). By deduction, amino acids 126–911 con-
tain a vault-interaction domain. A fourth TEP1 construct, con-
sisting of amino acids 201–1650 of murine TEP1, also
interacted with vaults even though it was poorly expressed
in insect cells, possibly due to the deletion of the TEP1 N-
terminus (data not shown). Therefore, the p80 region of TEP1
Figure 5. RNase H digests of vault-bound and deproteinated VR. (A)
Oligodeoxynucleotide-directed RNase H cleavage of the VR. P100 extract
(RNP) or deproteinized P100 (RNA) purified from rat fibroblasts (left panel)
or HeLa cells (right panel) was incubated with the indicated antisense ODN and
RNase H. RNA was extracted from each sample and fractionated on a 10%
denaturing polyacrylamide gel. The gel was electroblotted to a Zeta GT+ mem-
brane and probed with the randomly primed VR gene. Intact VR is indicated by
the arrow, and lower bands represent cleaved VR. (B) Thermodynamic predic-
tion of rat VR and human VR1 secondary structures. The lines indicate regions of
single-stranded RNA based upon RNase H digests of vault-associated VR.
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(amino acids 201–911) appears to contain both the RNA-
binding and vault-interaction domains. The VR is not present
in the baculovirus expression system, and Sf9 insect cells
do not contain endogenous vault components, so the TEP1–
vault interaction is not mediated by VR. The mapping of a
vault-interaction domain to this conserved region suggests the
intriguing possibility that Tetrahymena might contain vaults or
a protein conferring a related function. A database search of
the Tetrahymena genome did not identify an MVP homolog,
although assembly of the sequences for this genome is not yet
complete (The Institute for Genomic Research website at
http://www.tigr.org).
DISCUSSION
PSI-blast searches using the amino acid sequence of p80 have
previously identified two conserved regions that together span
the entire length of the protein. First, the TROVE (Telomerase,
Ro and Vault) module was identified as an evolutionarily
conserved (presumed) multi-domain region found in TEP1,
p80, Ro60 and a number of uncharacterized bacterial proteins
(30). This region spans amino acids 227–685 of murine TEP1.
Ro60 binds to small RNAs termed ‘Y RNAs’ along with the La
autoantigen in a small RNP complex and has been proposed to
contain an RNA recognition motif (RRM domain) based upon
the presence of RNP-1 and RNP-2 motifs that are the hallmark
of this domain (37,38). However, putative RRMs in p80 and
TEP1 have an unusually short spacing of the RNP-1 and RNP-
2 motifs and contain conserved polar residues in regions that
are non-polar in other RRMs (30). The second domain found
using databases searches of p80 is a von Willebrand type A
(vWA) domain, which can be involved in a number of func-
tions such as binding to metals, or mediating protein–protein
interactions, often in extracellular proteins or in multiprotein
complexes (39). This domain is also found adjacent to the
TROVE module in TEP1, and corresponds to amino acids
678–861 (29). Interestingly, a vWA domain is found in
VPARP as well (30). Our study indicates that an intact
TROVE module is required for RNA-binding activity, but
we were unable to remove the vWA sequences from the
p80 homology region of TEP1 in our yeast three-hybrid
assay without interfering with the ability of TEP1 to bind
RNA. Since vWA domains are not known to bind RNA, it
is possible that the removal of this region disrupts the con-
formation of the RNA-binding domain in the TROVE module.
An analysis of Ro60 similarly determined that even small
amino acid deletions in the protein led to the loss of binding
to Y RNAs, so it appears that this aspect of the two proteins has
also been conserved (40). As we have also mapped the vault-
interaction domain of TEP1 to the p80 homology region, either
the TROVE module or the vWA domain must mediate this
interaction. TEP1 interacts directly with MVP in the insect cell
expression system, and is not dependent upon VR for its asso-
ciation with vaults (29). Thus, it is not clear what mechanism
targets VR but not TR into the vault particle. One possibility is
that since the RNA-binding and vault-binding regions of TEP1
are either in close proximity or overlap, binding of TR to TEP1
could interfere with the ability of the protein to complex with
vaults, while binding of VR to TEP1 could promote the TEP1–
vault interaction. However, the effect of VR or TR on the
stability of the TEP1–vault association is difficult to assess
using the insect cell expression system, since the vault puri-
fication scheme incorporates an RNase treatment step to
remove ribosomes.
Since both VPARP and TEP1 associate with vaults and
telomerase (16,17,23), it is possible that there is a functional
connection between the two RNPs. The present study indicates
that VR or TR, but not both, can interact with a given TEP1
molecule, so it does not seem that VR could directly associate
with the telomerase complex via TEP1 without displacing TR.
Likewise, neither telomerase activity nor telomerase RNA has
been found associated with purified rat liver vaults or vaults
immunoprecipitated from tissue culture cells, respectively, so
it does not appear likely that either RNA is to be found in the
other RNP complex (13,26). The results of our RNase H
experiments suggest that the in vivo structure of the VR
diverges significantly from structure predictions based upon
thermodynamic models. Specifically, the left and right arms of
VR, which are essentially the only regions of the RNA that are
not conserved across species or even within a single species
Figure 6. The p80 homology region of TEP1 contains the vault interaction
domain. (A) TEP1 truncations were co-expressed with the MVP in Sf9 insect
cells using a baculovirus expression vector. (B) MVP forms vaults when
expressed in insect cells, which are found entirely in the high-speed pellet
(P100) of cell lysates and can be purified to near-homogeneity. Vault-inter-
acting proteins will co-purify with vaults. Vaults were further enriched, and as a
final step, samples were loaded onto a 20–60% sucrose gradient and centrifuged
for 16 h. Sucrose fractions were pelleted, resuspended in 20 mM MES buffer,
pH 6.5 and analyzed by western blot. Vaults fractionate largely in the 45%
sucrose layer (upper panel). In the absence () of MVP-baculovirus co-infec-
tion, TEP1 truncations fractionate in either the high-speed supernatant (S100),
P100, or both, and are lost in the purification scheme before the sucrose gradient
step (1, 2, and 3, upper panels). When MVP is present (+), TEP1 truncations able
to interact with vaults are found largely in the 45% sucrose layer (column 1, 2,
and 3, lower panels).
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when multiple VRs are present, are largely single stranded.
The central loop of purified endogenous VR is, therefore,
considerably larger than seems thermodynamically likely,
which may be due to binding of TEP1 to the conserved
lower region of the loop. It also seems likely that the in
vitro transcribed VR used in EMSA might fold into a structure
resembling the more thermodynamically favorable predicted
structures shown in Figure 5, rather than a structure containing
large stretches of single-stranded RNA. This would explain
why only a small fraction of the RNA interacts with TEP1–
RBD in vitro. Mutations in VR that disrupt base pairing near
the VR central loop enhance binding to TEP1 in vitro, which
suggests that this could be the case, and that these mutations
might partially compensate for the absence of factors promot-
ing the TEP1–VR interaction in vivo. Such missing factors
could include MVP, VPARP and, in particular, the La RNA-
binding protein, which binds VR stably apart from the vault
particle and loosely purifies with vaults, suggesting that it may
promote the VR–TEP1 interaction in vaults. Additionally,
the full-length TEP1 contains a putative NTPase motif, which
could potentially regulate the association of TEP1 with VR.
Thus far, we have been unable to purify sufficient quantities
of recombinant TEP1 containing both the p80 and putative
NTPase regions to test this hypothesis, since TEP1 is particu-
larly susceptible to degradation when expressed in insect cells.
Finally, it is difficult to rule out misfolding of either RNA or
the TEP1–RBD protein when conducting in vitro experiments
using purified components, either of which could affect the
specificity and stability of the RNA–protein interaction.
It was surprising that wild-type mouse VR did not readily
interact with TEP1–RBD, since human VR1, mutant mVR, TR
and a non-specific RNA did interact. Genetic evidence has
demonstrated that TEP1 directs VR to the vault particle and
influences its stability in vivo. Therefore, this study suggests
that additional components are probably required for TEP1 to
bind specifically to RNA. The complexity of reconstituting the
TEP1–VR interaction in vitro may explain why non-specific
binding of some RNAs to TEP1 is observed in the current
study, and also why studies of p80-TR binding also reported
non-specific binding of RNA (19). Overall, these results indic-
ate that binding of RNA to TEP1 may be regulated by other
cellular factors and suggest that the RNA-binding properties of
TEP1 in vitro are probably similar to those seen with p80.
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